The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCBX.L Regulatory News (CBX)

  • There is currently no data for CBX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Cellular Goods boosts team with five appointments

12 Apr 2021 07:00

RNS Number : 0615V
Cellular Goods PLC
12 April 2021
 

12 April 2021

 

 Cellular Goods PLC

("Cellular Goods" or "the Company")

 

Cellular Goods strengthens team with five new appointments

 

Cellular Goods (LSE: CBX), a UK-based provider of premium consumer products based on biosynthetic cannabinoids, is pleased to announce that it has appointed a new Head of Process and Applied Sciences, made two senior hires to its product development team and contracted two expert consultants to advise on the development of the Company's pet care and skincare ranges.

Istok Nahtigal joins as Head of Process and Applied Sciences to focus on Cellular Goods' cannabinoid supply chain and will be responsible for optimising the Company's relationships with its manufacturing partners. Istok is a Chartered Chemist and cannabis industry expert in the field of fermentation and bio-extractions. He has an impressive track record and his work has led to multiple inventions and patents in cannabinoid purification. Previously, Istok was a key scientific member of LAVVAN, a pioneering company focused on commercialising high-quality cannabinoid ingredients using synthetic biology, and MedReleaf Corp, one of the first Canadian producers of medical cannabis to receive a license from Health Canada. Prior to this, he held the role of Process Scientist at Bionche Life Sciences, leading the group evolving novel fermentation and downstream purification schemes for an E.coli vaccine.

Amanda Pape and Melissa Santolini join the product development team as Senior Quality Assurance Manager and Lead Project Manager respectively and will support Cellular Goods' product development, quality assurance, and roll out. Amanda is a healthcare professional with over 15 years of experience working in hospital diagnostic laboratories who has transferred her expertise to the cannabis industry. In 2020 Amanda founded her own quality assurance consulting company, working collaboratively with cannabis licensed providers to implement regulatory requirements and Quality Management Systems. Prior to this, she was also the Quality Assurance Manager at LAVVAN. Melissa has experience in the cannabis, pharmaceutical and agrochemical sectors. She was most recently at LAVVAN, where she focused on driving regulatory, product development and quality initiatives. Prior to LAVVAN, Melissa led product chemistry projects as a chemist at UPL Ltd, a global provider of crop protection chemicals, and held an analytical R&D role at Apotex Pharmachem Inc, a division of the Apotex group of companies.

Caroline Queen has been appointed as Pet Care Advisor and will provide consultancy regarding the development of Cellular's pet care range. This will include identifying suitable applications for cannabinoids in pet products and meeting associated regulatory and veterinary requirements. Caroline has an extensive background in the clinical and veterinary industry. She was formerly the Senior Business Development Director at Vet Partners Ltd, a veterinary group providing centralised support to individual practices across the UK.

Antony Buck has been appointed as Skincare Business Adviser and will be providing consultancy regarding the development of the Company's skincare range which will launch this year. In 2000 Antony created REN Skincare, a multi-award-winning brand that is sold in 50 countries and has a committed consumer base, with its range being sold predominantly in specialty stores and pharmacies. Antony successfully grew REN into a global brand with annual turnover excess of £40m before selling the business to Unilever in 2015.

Alexis Abraham, Chief Executive of Cellular Goods, commented: "Cellular Goods is executing on our differentiated business strategy: one focused on delivering clarity and consistent quality for consumers and leading the fast-moving consumer goods cannabinoid market through science and brand expertise. I am very pleased to welcome Istok, Caroline, Amanda, Melissa, and Antony. In their respective areas they complement our world-class team and will be a huge asset as we continue product development and gear up to releasing the first items in our skincare line this autumn." 

 

 

Cellular Goods

Alexis Abraham

Chief Executive

 

Neil Thapar

Investor Relations

+44 207 031 6871

 

 

 

+44 787 645 5323

Tennyson Securities

Corporate Broker

Peter Krens

 

+44 207 186 9030

Novum Securities

Corporate Broker

Colin Rowbury

Jon Belliss

 

+44 207 399 9427 

 

Tancredi Intelligent Communication

Media Relations

Helen Humphrey

Edward Daly

Salamander Davoudi

cellulargoods@tancredigroup.com

+44 744 922 6720

+44 786 143 0057

+44 795 754 9906

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGZGMDMMKGMZZ
Date   Source Headline
7th Nov 20067:02 amRNSDirector/PDMR Shareholding
25th Sep 20069:11 amRNSInterim Results
9th Aug 200610:43 amRNSAGM Statement
26th Jun 20067:01 amRNSFinal Results
28th Apr 200610:10 amRNSGrant of Options
21st Apr 200611:25 amRNSDirector/PDMR Shareholding
3rd Mar 20061:00 pmRNSAdmission to AIM-Amendment
3rd Mar 200612:23 pmRNSAdmission to AIM
7th Feb 20064:55 pmRNSSchedule 1 - Cubus Lux
7th Feb 20067:01 amRNSAcquisition
30th Sep 20051:33 pmRNSInterim Results
25th Jul 20053:25 pmRNSDirector/PDMR Shareholding
20th Jul 20057:00 amRNSOpening of a Third Casino
19th Jul 20056:09 pmRNSChange of Adviser
19th Jul 20056:09 pmRNSDirectorate Change
21st Mar 200512:07 pmRNSAnnual Report and Accounts
6th Jan 20055:52 pmRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.